Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRentokil Initial Regulatory News (RTO)

Share Price Information for Rentokil Initial (RTO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 418.10
Bid: 416.20
Ask: 416.40
Change: -1.50 (-0.36%)
Spread: 0.20 (0.048%)
Open: 421.30
High: 422.20
Low: 415.50
Prev. Close: 419.60
RTO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Q3 Trading Update

21 Oct 2021 07:00

RNS Number : 7297P
Rentokil Initial PLC
21 October 2021
 

  

 

21 October 2021

RENTOKIL INITIAL PLC (RTO) - THIRD QUARTER TRADING UPDATE

Strong momentum across our core businesses in Q3, continued good execution of M&A

 

 

(£m)

Q3 2021

Growth

AER

AER

CER

Ongoing Revenue1

761.3

0.9%

4.8%

Revenue

761.9

0.5%

4.4%

Excluding Disinfection

Ongoing Revenue1

750.2

10.2%

14.5%

Revenue

750.8

9.7%

14.0%

 

Overview of Q3 performance (at CER)

Q3 saw continued strong momentum in our core businesses with Group Ongoing Revenue, excluding disinfection services, growing by 14.5%, of which 6.7% was Organic2 and 7.8% was from acquisitions.

Pest Control delivered an excellent performance overall during the period. Despite our Australian, New Zealand, Malaysian and Indonesian operations being materially impacted by lockdowns in Q3, the category grew Ongoing Revenues by 18.3%, of which 7.5% was Organic. Ongoing Revenue in our Growth and Emerging markets grew by 18.7% and 15.6% respectively. In our North America business, a higher number of colleagues either off work with COVID-19 or self-isolating contributed to some labour shortages in the quarter. Despite this, our Pest Control business in North America continued to demonstrate very strong momentum, growing revenues by 24.6%, 10.1% Organic.

Our Core Hygiene business, excluding disinfection, delivered a 6.4% increase in Ongoing Revenue (4.7% Organic), reflecting good performances in the UK, Europe and Latin America but held back, as with Pest Control, by significant challenges associated with lockdowns and movement restrictions in Australia, New Zealand, Indonesia and Malaysia.

Sales from disinfection services have tapered in line with our expectations at £11.4m (Q1: £75.7m, Q2: £22.6m), a decline of £62.1m on this time last year. We are maintaining our guidance for disinfection revenues in H2 to be within the range of £10m to £20m.

Ongoing Revenue in our Protect & Enhance category grew by 6.2% (5.5% Organic), reflecting further recovery in our France Workwear, Ambius, UK Property Care and Dental Hygiene services businesses.

New category structure - Hygiene & Wellbeing

At our Capital Markets Day on 28 September, we announced that in response to the increasing importance of hygiene and wellbeing services, we are expanding our Hygiene category with effect from 1 January 2022. The enlarged category, called Hygiene & Wellbeing, will comprise our current Hygiene operations together with our Ambius, Dental Hygiene and Cleanroom services operations, previously part of our Protect & Enhance category. Adopting the new category structure in Q3 would give organic growth in Hygiene & Wellbeing of 6.6%.

M&A

​We completed nine acquisitions in Q3: seven in Pest Control; one in Hygiene; and the previously announced transaction with Boecker, which completed on 3 August and which offers both Pest Control and Hygiene services. As a result, we have acquired businesses with operations in Australia, Chile, Colombia, Guadeloupe, Lebanon, Saudi Arabia, United Arab Emirates and the US, as well as interests in affiliated businesses in Kuwait, Qatar and Nigeria. Together, these have combined annualised revenues in the year prior to acquisition of c.£48m. Q2's excellent momentum has been maintained in Q3 and also into Q4, and our anticipated full year expenditure on M&A remains in the region of at least £450m to £500m, as previously guided.

Commenting on today's announcement Andy Ransom, Chief Executive, said:

"We have delivered a strong performance from our core businesses in the quarter and are confident of sustaining this momentum for the remainder of the year. Assuming no further significant deterioration in trading conditions arising from the pandemic, our performance in Q3 - combined with further progress in our value-creating M&A programme - means we remain on track to deliver a full year performance in line with the guidance given at our interim results in July."

Enquiries:

 

Investors / Analysts:

Katharine Rycroft

Rentokil Initial plc

07811 270734

Media:

Malcolm Padley

Rentokil Initial plc

07788 978199

1Ongoing Revenue represents the performance of the continuing operations of the Group (including acquisitions) after removing the effect of disposed or closed businesses.

 

2Organic Revenue represents the growth in Ongoing Revenue excluding the effect of businesses acquired during the year. Acquired businesses are included in organic measures in the year following acquisition, and the comparative period is adjusted to include an estimated full year performance for growth calculations.

 

AER - actual exchange rates; CER - constant 2020 exchange rates

 

This announcement contains statements that are, or may be, forward-looking regarding the Group's financial position and results, business strategy, plans and objectives. Such statements involve risk and uncertainty because they relate to future events and circumstances and there are accordingly a number of factors which might cause actual results and performance to differ materially from those expressed or implied by such statements. Forward-looking statements speak only as of the date they are made and no representation or warranty, whether expressed or implied, is given in relation to them, including as to their completeness or accuracy or the basis on which they were prepared. Other than in accordance with the Company's legal or regulatory obligations (including under the Listing Rules and the Disclosure Guidance and Transparency Rules), the Company does not undertake any obligation to update or revise publicly any forward-looking statement, whether as a result of new information, future events or otherwise. Information contained in this announcement relating to the Company or its share price, or the yield on its shares, should not be relied upon as an indicator of future performance. Nothing in this announcement should be construed as a profit forecast.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTPPGUAUUPGGQU
Date   Source Headline
14th Oct 20224:39 pmRNSHolding(s) in Company
14th Oct 20224:37 pmRNSHolding(s) in Company
14th Oct 20229:30 amRNSAdditional Listing
13th Oct 20225:42 pmRNSHolding(s) in Company
13th Oct 20223:05 pmRNSHolding(s) in Company
12th Oct 20221:53 pmRNSAcquisition of Terminix Completion
10th Oct 20221:57 pmRNSHolding(s) in Company
10th Oct 20221:52 pmRNSHolding(s) in Company
10th Oct 20221:38 pmRNSHolding(s) in Company
7th Oct 20226:10 pmRNSRentokil Initial
6th Oct 20222:23 pmRNSResult of General Meeting
3rd Oct 20222:36 pmRNSBlock listing Interim Review
30th Sep 202211:42 amRNSDirector Declaration
14th Sep 20225:55 pmRNSDirector/PDMR Shareholding
14th Sep 202212:21 pmRNSDirector/PDMR Shareholding
7th Sep 20222:38 pmRNSPublication of Circular-Prospectus & GM Notice
22nd Aug 20227:00 amRNSHolding(s) in Company
5th Aug 20222:02 pmRNSDirector/PDMR Shareholding
28th Jul 20227:00 amRNS2022 Interim Results
27th Jul 20229:54 amRNSDirector Declaration
18th Jul 20223:11 pmRNSHolding(s) in Company
15th Jul 20225:30 pmRNSHolding(s) in Company
15th Jul 202211:57 amRNSHolding(s) in Company
27th Jun 20222:27 pmRNSPost stabilisation notice - Rentokil Initial Plc
22nd Jun 20224:16 pmRNSHolding(s) in Company
21st Jun 20223:37 pmRNSDirector/PDMR Shareholding
20th Jun 20229:12 amRNSPre stabilisation notice - Rentokil Initial Plc
20th May 202210:20 amRNSDirector/PDMR Shareholding
12th May 20227:00 amRNSResult of AGM
21st Apr 20227:00 amRNSQ1 Trading Update
1st Apr 20227:00 amRNSBlock listing Interim Review
31st Mar 20226:15 pmRNSTotal Voting Rights
30th Mar 20229:44 amRNSAnnual Financial Report
29th Mar 20222:20 pmRNSDirector/PDMR Shareholding
25th Mar 20224:31 pmRNSDirector/PDMR Shareholding
15th Mar 20227:00 amRNSUpdate on Terminix acquisition
14th Mar 202211:00 amRNSAdditional Listing
3rd Mar 20227:00 amRNSFinal Results
2nd Mar 202210:29 amRNSDirector/PDMR Shareholding
28th Feb 20224:47 pmRNSHolding(s) in Company
22nd Dec 20215:38 pmRNSDirector/PDMR Shareholding
21st Dec 20214:09 pmRNSDirector/PDMR Shareholding
16th Dec 20217:00 amRNSFurther re Terminix Acqn S&P reaffirms BBB rating
15th Dec 20212:02 pmRNSDirector/PDMR Shareholding
14th Dec 20217:00 amRNSAcquisition of Terminix by Rentokil Initial plc
22nd Oct 202110:42 amRNSDirector Declaration
21st Oct 20217:00 amRNSQ3 Trading Update
1st Oct 202110:00 amRNSBlock listing Interim Review
28th Sep 20217:00 amRNSNotice of Capital Markets Day
17th Aug 20216:09 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.